MedTrace Logo

Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

NCT00904423 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-02-14

Study results available
· View outcomes & findings →

Summary

Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include bone loss, fractures, arthralgias and myalgias. We hypothesize vitamin D administration might be beneficial in treating these symptoms and to protect bone.

Conditions

Interventions

DRUG

Vitamin D

up to 2400 mg; oral tablet

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Mark Pegram

    lead OTHER

Principal Investigators

  • Eva Balint · Stanford University

  • Robert W Carlson · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904423 on ClinicalTrials.gov